[1] |
|
[2] |
LIU W Z, XIE Y, LU H,et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection[J]. Helicobacter, 2018, 23(2):e12475. DOI: 10.1111/hel.12475.
|
[3] |
HOOI J K Y, LAI W Y, NG W K,et al. Global prevalence of Helicobacter pylori infection:systematic review and meta-analysis[J]. Gastroenterology, 2017, 153(2):420-429. DOI: 10.1053/j.gastro.2017.04.022.
|
[4] |
MALFERTHEINER P, MEGRAUD F, O'MORAIN C A,et al. Management of Helicobacter pylori infection-the maastricht V/Florence consensus report[J]. Gut, 2017, 66(1):6-30. DOI: 10.1136/gutjnl-2016-312288.
|
[5] |
ZOU P Y, HU J, ZHAO J T,et al. 10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori:a propensity score matching analysis[J]. Helicobacter, 2021, 26(5):e12833. DOI: 10.1111/hel.12833.
|
[6] |
SONG Z Q, ZHOU L Y, XUE Y,et al. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication:a randomized trial[J]. Helicobacter, 2020, 25(6):e12762. DOI: 10.1111/hel.12762.
|
[7] |
YU L, LUO L S, LONG X H,et al. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy:a randomized trial[J]. Helicobacter, 2019, 24(4):e12596. DOI: 10.1111/hel.12596.
|
[8] |
YANG J, ZHANG Y, FAN L,et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori[J]. Am J Gastroenterol, 2019, 114(3):437-445. DOI: 10.14309/ajg.0000000000000132.
|
[9] |
|
[10] |
|
[11] |
|
[12] |
LIU D S, WANG Y H, ZHU Z H,et al. Characteristics of Helicobacter pylori antibiotic resistance:data from four different populations[J]. Antimicrob Resist Infect Control, 2019, 8:192. DOI: 10.1186/s13756-019-0632-1.
|
[13] |
REN L, LU H, LI H Y,et al. New dual therapy for primary treatment of Helicobacter pylori infection:a prospective randomized study in Shanghai,China[J]. J Dig Dis, 2014, 15(11):622-627. DOI: 10.1111/1751-2980.12186.
|
[14] |
GAO W, YE H, DENG X,et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients:a retrospective,real-life study[J]. Helicobacter, 2020, 25(5):e12717. DOI: 10.1111/hel.12717.
|
[15] |
ÖZTÜRK K, KURT Ö, ÇELEBI G,et al. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection[J]. Turk J Gastroenterol, 2020, 31(3):234-238. DOI: 10.5152/tjg.2020.18974.
|
[16] |
GOH K L, MANIKAM J, QUA C S. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures[J]. Aliment Pharmacol Ther, 2012, 35(9):1097-1102. DOI: 10.1111/j.1365-2036.2012.05054.x.
|
[17] |
HU Y M, XU J M, MEI Q,et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects[J]. Acta Pharmacol Sin, 2005, 26(3):384-388. DOI: 10.1111/j.1745-7254.2005.00047.x.
|
[18] |
RESHETNYAK V I, RESHETNYAK T M. Significance of dormant forms of Helicobacter pylori in ulcerogenesis[J]. World J Gastroenterol, 2017, 23(27):4867-4878. DOI: 10.3748/wjg.v23.i27.4867.
|
[19] |
DE FRANCESCO V, ZULLO A, PERNA F,et al. Helicobacter pylori antibiotic resistance and [13C] urea breath test values[J]. J Med Microbiol, 2010, 59(Pt 5):588-591. DOI: 10.1099/jmm.0.018077-0.
|
[20] |
BODEY G P, NANCE J. Amoxicillin:in vitro and pharmacological studies[J]. Antimicrob Agents Chemother, 1972, 1(4):358-362. DOI: 10.1128/AAC.1.4.358.
|
[21] |
GERRITS M M, GODOY A P O, KUIPERS E J,et al. Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori[J]. Helicobacter, 2006, 11(3):181-187. DOI: 10.1111/j.1523-5378.2006.00398.x.
|
[22] |
HU Y, ZHU Y, LU N H. Primary antibiotic resistance of Helicobacter pylori in China[J]. Dig Dis Sci, 2017, 62(5):1146-1154. DOI: 10.1007/s10620-017-4536-8.
|
[23] |
SHAO Y F, LU R D, YANG Y B,et al. Antibiotic resistance of Helicobacter pylori to 16 antibiotics in clinical patients[J]. J Clin Lab Anal, 2018, 32(4):e22339. DOI: 10.1002/jcla.22339.
|
[24] |
MOHAMMADI M, ATTARAN B, MALEKZADEH R,et al. Furazolidone,an underutilized drug for H.pylori eradication:lessons from Iran[J]. Dig Dis Sci, 2017, 62(8):1890-1896. DOI: 10.1007/s10620-017-4628-5.
|
[25] |
|
[26] |
GAO C P, ZHANG D, ZHANG T,et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection:an update based on a systematic review and meta-analysis[J]. Helicobacter, 2020, 25(4):e12692. DOI: 10.1111/hel.12692.
|
[27] |
ZHANG Y, ZHU Y J, ZHAO Z,et al. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection:an open-label,randomized trial[J]. Eur J Gastroenterol Hepatol, 2020, 32(5):563-568. DOI: 10.1097/MEG.0000000000001646.
|
[28] |
|